Total Funding
23
38
Total FundingSeries E raised
Growth Score
-1 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
78066
MicuRx discovers and develops novel antimicrobials to treat drug-resistant infections and other diseases of significant unmet medical need
- Xinghai Wang: Chief Technology Officer and Deputy General Manager
Mike F. Gordeev: Co-Founder & Special Consultant, CSO
About the Company
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was
established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
